Joseph Lyssikatos Sells 20,000 Shares of Enliven Therapeutics (NASDAQ:ELVN) Stock

Enliven Therapeutics, Inc. (NASDAQ:ELVN) insider Joseph Lyssikatos sold 20,000 shares of Enliven Therapeutics stock in a transaction on Tuesday, January 20th. The shares were sold at an average price of $26.75, for a total transaction of $535,000.00. Following the completion of the sale, the insider directly owned 745,188 shares in the company, valued at $19,933,779. This represents a 2.61% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Enliven Therapeutics Trading Down 0.6%

NASDAQ:ELVN traded down $0.17 during trading hours on Thursday, reaching $27.03. 1,466,778 shares of the company were exchanged, compared to its average volume of 1,935,634. The firm has a market cap of $1.60 billion, a PE ratio of -14.69 and a beta of 0.41. Enliven Therapeutics, Inc. has a twelve month low of $13.30 and a twelve month high of $29.98. The stock’s 50-day moving average is $20.22 and its 200-day moving average is $20.27.

Enliven Therapeutics (NASDAQ:ELVN) last announced its earnings results on Thursday, November 13th. The company reported ($0.32) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.43) by $0.11. As a group, research analysts anticipate that Enliven Therapeutics, Inc. will post -1.95 EPS for the current year.

Hedge Funds Weigh In On Enliven Therapeutics

Several large investors have recently made changes to their positions in the stock. BNP Paribas Financial Markets raised its position in Enliven Therapeutics by 33.3% in the second quarter. BNP Paribas Financial Markets now owns 3,722 shares of the company’s stock valued at $75,000 after purchasing an additional 930 shares during the period. Quantbot Technologies LP boosted its position in shares of Enliven Therapeutics by 47.1% during the second quarter. Quantbot Technologies LP now owns 4,477 shares of the company’s stock worth $90,000 after buying an additional 1,434 shares during the period. AlphaQuest LLC purchased a new stake in shares of Enliven Therapeutics in the 3rd quarter valued at $96,000. Tower Research Capital LLC TRC increased its stake in Enliven Therapeutics by 194.3% during the second quarter. Tower Research Capital LLC TRC now owns 5,286 shares of the company’s stock worth $106,000 after purchasing an additional 3,490 shares during the period. Finally, KLP Kapitalforvaltning AS increased its stake in Enliven Therapeutics by 58.1% during the 2nd quarter. KLP Kapitalforvaltning AS now owns 6,800 shares of the company’s stock worth $136,000 after buying an additional 2,500 shares during the period. 95.08% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on ELVN shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Enliven Therapeutics in a research note on Wednesday, October 8th. Wall Street Zen raised shares of Enliven Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, November 15th. Four analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $41.00.

About Enliven Therapeutics

Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.

The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications.